Inventor · disambiguated record
Elizabeth Gabitzsch
Also filed as: GABITZSCH ELIZABETH
13 granted patents·9 pending applications·40 citations·filing 2013–2025
88Inventor score
Top patents by PatentIndex Score
22 records- 0193US10695417B2Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoproteinETUBICS CORP·Filed 2016·Granted Jun 30, 2020·9 cites·25 claims
- 0291US11104916B2Compositions and methods for alphavirus vaccinationETUBICS CORP·Filed 2017·Granted Aug 31, 2021·6 cites·17 claims
- 0391US10563224B2Replication defective adenovirus vector in vaccinationETUBICS CORP·Filed 2017·Granted Feb 18, 2020·5 cites·18 claims
- 0488US9605276B2Replication defective adenovirus vector in vaccinationJONES FRANK R·Filed 2013·Granted Mar 28, 2017·12 cites·22 claims
- 0587US11304998B2Combination immunotherapies comprising IL-15 superagonistsETUBICS CORP·Filed 2021·Granted Apr 19, 2022·1 cites·9 claims
- 0683US11149087B2Methods and compositions for combination immunotherapyETUBICS CORP·Filed 2016·Granted Oct 19, 2021·2 cites·25 claims
- 0781US12290558B2SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogensIMMUNITYBIO INC·Filed 2023·Granted May 6, 2025·0 cites·11 claims
- 0881US11116827B2Compositions and methods for tumor vaccination and immunotherapy involving HER antigensETUBICS CORP·Filed 2018·Granted Sep 14, 2021·1 cites·14 claims
- 0981US11020467B2Combination immunotherapies comprising IL-15 superagonistsETUBICS CORP·Filed 2018·Granted Jun 1, 2021·1 cites·10 claims
- 1080US12274748B2Adenoviral vector transduced apheresis productIMMUNITYBIO INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 1179US10835596B2Compositions and methods for flavivirus vaccinationETUBICS CORP·Filed 2017·Granted Nov 17, 2020·2 cites·16 claims
- 1269US2025235530A1Anti COVID-19 Therapies targeting nucleocapsid and spike proteinsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1368US11857620B2Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirusIMMUNITYBIO INC·Filed 2021·Granted Jan 2, 2024·0 cites·11 claims
- 1464US11352642B2Methods and compositions for combination immunotherapyETUBICS CORP·Filed 2016·Granted Jun 7, 2022·1 cites·14 claims
- 1562US2025242025A1Adenoviral Vector Transduced Apheresis ProductIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1661US2023348935A1Vaccine compositions for mucosal immune responseNANT HOLDINGS IP LLC·Filed 2021·Application pending·0 cites
- 1750US2025383359A1COVID-19 Mucosal Antibody AssayNANTCELL INC·Filed 2021·Application pending·0 cites
- 1844US2019022209A1Methods and compositions for influenza vaccinationETUBICS CORP·Filed 2017·Application pending·0 cites
- 1943US2019125852A1Compositions and methods for tumor vaccination using prostate cancer-associated antigensETUBICS CORP·Filed 2017·Application pending·0 cites
- 2043US2019134195A1Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseasesETUBICS CORP·Filed 2017·Application pending·0 cites
- 2142US2019134174A1Compositions and methods for tumor vaccination and immunotherapy involving her2/neuETUBICS CORP·Filed 2017·Application pending·0 cites
- 2240US2019030151A1Methods and compositions for t-cell immunotherapyETUBICS CORP·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elizabeth Gabitzsch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →